Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAF(V600)-Mutated Nonmelanoma Tumors

BRAF(V600) mutations occur in multiple nonmelanoma tumors, but no US Food and Drug Administration–approved BRAF-targeted therapies exist for these cancers. BRAF inhibitor vemurafenib was recently found to demonstrate activity across various BRAF-mutated nonmelanoma cancer types. However, most tumors...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Natl Cancer Inst
Main Authors: Sen, Shiraj, Meric-Bernstam, Funda, Hong, David S., Hess, Kenneth R., Subbiah, Vivek
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Brief Communications
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6059192/
https://ncbi.nlm.nih.gov/pubmed/29117359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djx094
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki